Jim Simons Adagene Inc. Transaction History

Renaissance Technologies LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$1.17 - $1.76 $24,849 - $37,380	-21,239 Reduced 53.58%	18,402 $27,000
Q1 2023 May 12, 2023	SELL	$1.27 - $1.95 $44,397 - $68,170	-34,959 Reduced 46.86%	39,641 $57,000
Q4 2022 Feb 13, 2023	SELL	$0.9 - $1.46 $19,080 - $30,952	-21,200 Reduced 22.13%	74,600 $99,000
Q3 2022 Nov 14, 2022	BUY	$1.24 - $2.09 $91,767 - $154,672	74,006 Added 339.57%	95,800 $123,000
Q2 2022 Aug 12, 2022	BUY	$1.99 - $3.85 $43,370 - $83,906	21,794 New	21,794 $45,000

9.87M

Ticker ADAG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,423,200
Market Cap $89M
Description
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.